These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36682147)

  • 1. Structure optimization, synthesis, and biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)-quinazolin-4(3H)-one derivatives as potential multi-targeted anticancer agents via Aurora A/ PI3K/BRD4 inhibition.
    Fan Y; Luo F; Su M; Li Q; Zhong T; Xiong L; Li M; Yuan M; Wang D
    Bioorg Chem; 2023 Mar; 132():106352. PubMed ID: 36682147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition.
    Fan C; Zhong T; Yang H; Yang Y; Wang D; Yang X; Xu Y; Fan Y
    Eur J Med Chem; 2020 Mar; 190():112108. PubMed ID: 32058239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition.
    Yang H; Li Q; Su M; Luo F; Liu Y; Wang D; Fan Y
    Bioorg Med Chem; 2021 Sep; 46():116346. PubMed ID: 34403956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors.
    Zheng YG; Wang JA; Meng L; Pei X; Zhang L; An L; Li CL; Miao YL
    Eur J Med Chem; 2021 Jan; 209():112934. PubMed ID: 33109396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
    Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
    Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis and Biological Evaluation of 6-(Imidazo[1,2-a]pyridin-6-yl)quinazoline Derivatives as Anticancer Agents via PI3Kα Inhibition.
    Li M; Wang D; Li Q; Luo F; Zhong T; Wu H; Xiong L; Yuan M; Su M; Fan Y
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of 6-(imidazo[1,2-a] pyridin-6-yl) quinazolin-4(3H)-one derivatives as potent anticancer agents by dual targeting Aurora kinase and ROR1.
    Fan Y; Zhang F; Xiong L; Su M; Luo F; Li M; Li Q; Zhong T; Yuan M; Xu Y; Mu S; Yang H
    Bioorg Chem; 2023 Jun; 135():106484. PubMed ID: 36963371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
    Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
    Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer.
    Dong C; Chen Y; Li H; Yang Y; Zhang H; Ke K; Shi XN; Liu X; Li L; Ma J; Kung HF; Chen C; Lin MC
    Int J Biol Sci; 2019; 15(7):1523-1532. PubMed ID: 31337981
    [No Abstract]   [Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
    Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
    Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PI3Kα inhibitor DFX24 suppresses tumor growth and metastasis in non-small cell lung cancer via ERK inhibition and EPHB6 reactivation.
    Fan YH; Ding HW; Kim D; Liu JY; Hong JY; Xu YN; Wang D; Yang XS; Lee SK
    Pharmacol Res; 2020 Oct; 160():105147. PubMed ID: 32814167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and anticancer evaluation of novel 1H-benzo[d]imidazole derivatives of dehydroabietic acid as PI3Kα inhibitors.
    Yang YQ; Chen H; Liu QS; Sun Y; Gu W
    Bioorg Chem; 2020 Jul; 100():103845. PubMed ID: 32344183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors.
    Bo YX; Xiang R; Xu Y; Hao SY; Wang XR; Chen SW
    Bioorg Med Chem; 2020 Mar; 28(5):115351. PubMed ID: 32035750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
    Kong B; Zhu Z; Li H; Hong Q; Wang C; Ma Y; Zheng W; Jiang F; Zhang Z; Ran T; Bian Y; Yang N; Lu T; Zhu J; Tang W; Chen Y
    Eur J Med Chem; 2022 Jan; 227():113953. PubMed ID: 34731760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization and biological evaluation of nicotinamide derivatives as Aurora kinase inhibitors.
    Qi B; Xu X; Yang Y; He H; Yue X
    Bioorg Med Chem; 2019 Sep; 27(17):3825-3835. PubMed ID: 31307762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Approaches for the Synthesis of Heterocyclic Compounds Corporating Benzo[d]imidazole as Anticancer Agents, Tyrosine, Pim-1 Kinases Inhibitions and their PAINS Evaluations.
    Mohareb RM; Milad YR; Mostafa BM; El-Ansary RA
    Anticancer Agents Med Chem; 2021; 21(3):327-342. PubMed ID: 32698742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR
    Ding S; Dong X; Gao Z; Zheng X; Ji J; Zhang M; Liu F; Wu S; Li M; Song W; Shen J; Duan W; Liu J; Chen Y
    Bioorg Chem; 2022 Jan; 118():105471. PubMed ID: 34798457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring new quinazolin-4(3H)-one derivatives as CDK2 inhibitors: Design, synthesis, and anticancer evaluation.
    Ibrahim BT; Allam HA; El-Dydamony NM; Fouad MA; Mohammed ER
    Drug Dev Res; 2024 Apr; 85(2):e22163. PubMed ID: 38419305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors.
    Li X; Zhang J; Zhao L; Yang Y; Zhang H; Zhou J
    ChemMedChem; 2018 Jul; 13(13):1363-1368. PubMed ID: 29808961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.